Management provides a clinical update from the Phase 1/2 ABILITY Study on a conference call to be held on August 9 at 8:30 am. Webcast Link
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDNA:
- Medicenna Therapeutics completes MDNA11 dose escalation
- Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study
- Medicenna Therapeutics to host conference call
- Medicenna Therapeutics appoints Yavari as Chair of DAC
- Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee